Equities analysts expect that Teladoc Health Inc (NYSE:TDOC) will post earnings per share (EPS) of ($0.35) for the current quarter, according to Zacks. Ten analysts have made estimates for Teladoc Health’s earnings, with estimates ranging from ($0.40) to ($0.22). Teladoc Health posted earnings per share of ($0.50) in the same quarter last year, which would suggest a positive year-over-year growth rate of 30%. The firm is scheduled to issue its next earnings results on Tuesday, February 26th.
On average, analysts expect that Teladoc Health will report full-year earnings of ($1.47) per share for the current financial year, with EPS estimates ranging from ($1.52) to ($1.33). For the next year, analysts expect that the business will post earnings of ($1.03) per share, with EPS estimates ranging from ($1.40) to ($0.29). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Teladoc Health.
Teladoc Health (NYSE:TDOC) last announced its quarterly earnings results on Thursday, November 1st. The health services provider reported ($0.34) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.02. Teladoc Health had a negative return on equity of 14.05% and a negative net margin of 31.32%. The business had revenue of $111.00 million for the quarter, compared to the consensus estimate of $109.94 million. During the same period last year, the business posted ($0.55) EPS. The business’s revenue was up 61.6% compared to the same quarter last year.
Several equities analysts have recently issued reports on the company. KeyCorp boosted their price objective on Teladoc Health from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Friday, September 28th. TheStreet lowered Teladoc Health from a “c” rating to a “d+” rating in a research note on Tuesday, October 9th. Chardan Capital boosted their price objective on Teladoc Health from $73.00 to $86.00 and gave the stock a “buy” rating in a research note on Friday, August 3rd. Robert W. Baird upped their price target on Teladoc Health from $50.00 to $65.00 and gave the company a “neutral” rating in a research report on Wednesday, July 25th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $70.00 price objective on shares of Teladoc Health in a research report on Thursday, August 2nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $82.95.
Teladoc Health stock opened at $62.49 on Friday. The company has a current ratio of 8.99, a quick ratio of 8.99 and a debt-to-equity ratio of 0.40. The stock has a market cap of $4.45 billion, a price-to-earnings ratio of -37.87 and a beta of 0.96. Teladoc Health has a fifty-two week low of $27.30 and a fifty-two week high of $89.05.
In other Teladoc Health news, insider Lewis Levy sold 1,285 shares of the company’s stock in a transaction dated Wednesday, August 15th. The shares were sold at an average price of $70.80, for a total value of $90,978.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Stephany Verstraete sold 18,000 shares of the stock in a transaction that occurred on Thursday, September 20th. The shares were sold at an average price of $74.79, for a total transaction of $1,346,220.00. Following the completion of the transaction, the insider now owns 13,925 shares of the company’s stock, valued at $1,041,450.75. The disclosure for this sale can be found here. In the last 90 days, insiders sold 235,930 shares of company stock worth $17,033,927. Company insiders own 3.95% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Oppenheimer Asset Management Inc. lifted its position in Teladoc Health by 9.7% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 9,789 shares of the health services provider’s stock worth $845,000 after buying an additional 862 shares in the last quarter. CWM LLC grew its stake in Teladoc Health by 2.1% in the 2nd quarter. CWM LLC now owns 53,632 shares of the health services provider’s stock valued at $3,113,000 after buying an additional 1,078 shares during the last quarter. Swiss National Bank grew its stake in Teladoc Health by 1.2% in the 3rd quarter. Swiss National Bank now owns 97,900 shares of the health services provider’s stock valued at $8,454,000 after buying an additional 1,200 shares during the last quarter. HAP Trading LLC grew its position in Teladoc Health by 6.8% in the 3rd quarter. HAP Trading LLC now owns 19,650 shares of the health services provider’s stock worth $1,697,000 after purchasing an additional 1,250 shares during the last quarter. Finally, Amalgamated Bank grew its position in Teladoc Health by 22.3% in the 2nd quarter. Amalgamated Bank now owns 9,472 shares of the health services provider’s stock worth $550,000 after purchasing an additional 1,724 shares during the last quarter.
About Teladoc Health
Teladoc Health, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Featured Article: What factors cause inflation to rise?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.